Taken together, it appears safe to conclude from the published data so far, that patients with IBD in general are not at an increased risk for a severe clinical course of COVID-19 and that neither TNF-, IL-12/23 – nor intergrin blockade could be identified as a risk factor, thus, emphasizing that these therapies should be continued in IBD patients. Here, TNF is linked to irritable bowel syndrome.